Please login to the form below

Not currently logged in
Email:
Password:

wet AMD

This page shows the latest wet AMD news and features for those working in and with pharma, biotech and healthcare.

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

It’s due for launch in Europe in the second quarter. Novartis and partner Roche have been head-to-head with Bayer in the wet AMD market for years, with Eylea ... aflibercept) squaring off against Novartis’ older drug Lucentis (ranibizumab), the first

Latest news

More from news
Approximately 20 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD). ... Coincidentally two weeks earlier, there was another deal for a

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐endoglin antibodies, including TRC105 for wet AMD (p2).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    effectiveness over Novartis' Lucentis (ranibizumab) in the treatment of wet age-related macular degeneration (AMD).

  • Revolution or evolution: is it the end of SMR and ASMR in France? Revolution or evolution: is it the end of SMR and ASMR in France?

    An example of this is Lucentis in wet age-related macular degeneration (AMD), where the expectation is that there should be pricing parity between Lucentis and Avastin, an oncology drug used

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics